Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine  by Wijesinghe, Pushpa Ranjan et al.
Vaccine 34 (2016) 5923–5928Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineImmunogenicity of live attenuated Japanese encephalitis SA 14-14-2
vaccine among Sri Lankan children with previous receipt of inactivated
JE vaccinehttp://dx.doi.org/10.1016/j.vaccine.2016.10.028
0264-410X/ 2016 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author at: PO Box 900922, Seattle, WA 98109, USA.
E-mail address: cvictor@path.org (J.C. Victor).Pushpa Ranjan Wijesinghe a, M.R. Nihal Abeysinghe a, Sutee Yoksan b, Yafu Yao c, Benli Zhou c, Lei Zhang c,
Jessica A. Fleming d, Anthony A. Marfin d, John C. Victor d,⇑
a Epidemiological Unit, Ministry of Healthcare and Nutrition, Colombo, Sri Lanka
bMahidol University, Bangkok, Thailand
cChengdu Institute of Biological Products, Chengdu, China
d PATH, Seattle, WA, USAa r t i c l e i n f o
Article history:
Received 11 August 2016
Received in revised form 5 October 2016
Accepted 6 October 2016
Available online 20 October 2016
Keywords:
Japanese encephalitis vaccines
Clinical trial
Humoral immune response
Secondary immune response
Safetya b s t r a c t
Background: The performance of live attenuated Japanese Encephalitis SA 14-14-2 vaccine (CD-JEV)
among children previously given inactivated mouse brain-derived JE vaccine (IMBV) is unknown. We
evaluated the safety and immunogenicity of CD-JEV administered to 2- and 5-year-old children in Sri
Lanka.
Methods: In this open-label, single arm trial in the Colombo District of Sri Lanka, generally healthy chil-
dren 2 and 5 years of age who had previously received two and three doses of IMBV, respectively, were
administered one dose of CD-JEV subcutaneously. Participants were monitored for adverse events for one
year post-vaccination. Serum neutralizing antibody responses were evaluated pre and 28 and 365 days
post-vaccination using JE plaque reduction neutralization test and characterized as the proportion of par-
ticipants seroconverting. Seroconversion was defined as either reaching a titer considered seroprotective
(P1:10) among participants with a baseline titer <1:10 or achieving at least a 4-fold rise in titer among
participants with a baseline titer P1:10.
Results: Of 305 children given CD-JEV, 294 were included in the primary analysis of immunogenicity.
Prior to vaccination, 144/147 (98.0%) 2-year-olds and 146/147 (99.3%) 5-year-olds had seroprotective
levels. 28 days post-vaccination, 79/147 [53.7% (95% CI, 45.3–62.0)] 2-year olds and of 60/147 [40.8%
(95% CI, 32.8–49.2)] 5-year olds achieved seroconversion. Among 2-year-olds, geometric mean titers
(GMTs) rose from 697 to 3175 28 days post-vaccination. Among 5-year-olds, GMTs rose from 926 to
2776. Most adverse reactions were mild, and no serious adverse events were related to study vaccination.
Conclusion: Administration of CD-JEV to these children with pre-existing neutralizing JE antibody titers
was safe and resulted in substantial boosting of antibody levels. These results may inform other countries
in Asia considering switching from IMBV to now WHO-prequalified CD-JEV vaccine to combat this
disease of public health importance.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Japanese encephalitis (JE) is a flavivirus that is transmitted
primarily by Culex mosquitoes from South Asia to regions of the
Western Pacific. JE infection is usually asymptomatic, but
symptomatic infections of the brain can be severe, resulting in both
permanent brain damage and death. These sequelae, especially
among children, and infections occurring among many peopleduring large outbreaks is why JE is a disease of public health
concern [1,2]. Because the virus is zoonotic in regions where it is
endemic, vaccines are the primary tool for disease control.
In several countries in Asia, such as Sri Lanka, national
immunization programs previously relied on inactivated mouse
brain-derived vaccine (IMBV), given in multiple doses (in primary
series and as booster doses). New JE vaccines are now available [3].
Switching from IMBV to a new JE vaccine would be programmati-
cally simpler if countries did not need to ensure a completed series
with IMBV and could simply give children who had initiated the
IMBV series a dose(s) of the new JE vaccine. One new JE vaccine,
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SA 14-14-2 JE vaccine (CD-JEV), can be given as a single dose [4].
However, it is unknown how CD-JEV would perform after adminis-
tration to children with antibodies induced by previous receipt of
IMBV. To address this question and provide officials with locally
generated immunogenicity and safety data on CD-JEV, the Sri
Lanka Ministry of Healthcare and Nutrition initiated this study.2. Methods
2.1. Study design
The study was an open label, non-randomized, single-arm trial,
conducted in three peri-urban health divisions with low JE
endemicity in the District of Colombo. Ethical review was provided
by the University of Colombo Faculty of Medicine Ethical Review
Committee and PATH’s Research Ethics Committee. Parents or
guardians provided written informed consent for all participants.
The study, ClinicalTrials.gov NCT00463476, was conducted accord-
ing to the principles of the Declaration of Helsinki. PATH sponsored
the trial and ensured its compliance with Good Clinical Practice
(GCP) guidelines.
2.2. Participants
Eligible participants were generally healthy children aged
2 years (plus or minus 3 months) and 5 years (plus or minus
3 months) who had previously received all vaccinations recom-
mended under the Sri Lankan childhood immunization schedule
according to their age and would attend all planned study visits.
Children 2 years of age must have previously received IMBV at
the recommended 12 and 13 months of age, and children 5 years
of age must have previously received IMBV at the recommended
12, 13, and 24 months of age. Children with a history of acute
encephalitis were excluded. Participants were requested to forego
other vaccinations from 2 weeks before to 4 weeks after receipt of
study vaccine.
2.3. Procedures
Participants were consecutively enrolled as consent was
obtained. On study day 0, participants received a single 0.5 ml dose
of CD-JEV (live attenuated SA 14-14-2 JE vaccine, CDIBP, Chengdu,
People’s Republic of China; lot 200611A078-1) delivered subcuta-
neously in the right upper arm using 23 gauge needles.
Participants were monitored by trained study physicians. Dur-
ing the first 7 days after vaccination, parents completed diary cards
for solicited and unsolicited events, grading events according to
severity using scales supplied to them by study physicians. Study
physicians called or visited the homes of participants 2–3 days
after receipt of CD-JEV to review diary cards and assist parents
with my severity grading problems. On the 7th day post-
vaccination, study physicians visited all homes of study subjects,
reviewed diary cards with parents, and performed a physical exam
of the participant. At 28 days post-vaccination, parents returned to
the study clinic with their child participant, and study physicians
interviewed parents about additional unsolicited events and again
performed a physical exam. Over the subsequent 10 months, par-
ticipants were visited or telephoned monthly by study physicians
to identify serious adverse events (SAEs). Finally, at one year
post-vaccination, parents returned to the study clinic with their
child participant for a final visit where physicians performed a final
physical exam. During face-to-face visits, ongoing AEs were graded
for severity by study physicians. Participants provided blood serum
at enrollment and approximately 28 days and one year post-vaccination. Serum samples were frozen at 70 C and shipped
by air on dry ice to the Center for Vaccine Development at Mahidol
University in Bangkok for testing.2.4. Outcomes
The primary immunogenicity endpoint was the titer of serum
neutralizing antibody to JE. Neutralizing antibodies were measured
by plaque reduction neutralization test (PRNT); the method used
was a serum dilution, constant virus PRNT50 performed in LLC-
MK2 cells [5]. Paired serum samples from subjects were tested
for antibodies against wild-type Beijing-1 strain, a JE virus belong-
ing to JE virus genotype III, the same genotype as CD-JEV. The end-
point for neutralization was the inverse of the dilution at which
plaque counts were reduced by 50%, compared with a negative
serum control, determined by probit analysis. Seroprotection for
JE was defined as a serum neutralizing antibody titer ofP1:10 [6].
Safety endpoints included solicited local reactions at the injec-
tion site (erythema, induration, and pain), solicited systemic reac-
tions (fever, anorexia, crying, diarrhea, drowsiness, insomnia,
irritability, and vomiting), and unsolicited adverse reactions
through 7 days post-vaccination. Other unsolicited non-serious
adverse events from 8 through 28 days post-vaccination and SAEs
at any time during the 1-year study were also collected. SAEs were
defined by ICH GCP with the additional criterion that other ‘‘impor-
tant medical events that may not result in death, be life threaten-
ing, or require hospitalization may be considered SAEs when, based
upon appropriate medical judgment, may jeopardize the subject
and may require medical or surgical intervention to prevent one
of the outcomes listed by ICH GCP.”2.5. Statistical analyses
The primary objective was to estimate the proportion of 2-year-
old and 5-year-old children with seroprotective levels of JE serum
neutralizing antibodies 28 days post-vaccination. The secondary
objectives were to determine the proportion of children in each
age group with seroprotective levels at one year post-vaccination
and the geometric mean titer (GMT) of serum neutralizing antibod-
ies to JE at 28 days and one year post-vaccination for both groups.
Titers less than the limit of quantification (1:10) were assigned a
value of 1:5 for calculation of GMTs. Exact 95% confidence intervals
for proportions were calculated under the binomial distribution,
and approximate 95% confidence intervals for log GMTs were cal-
culated under the normal distribution. Because WHO recommends
that ‘‘In people who are seropositive at baseline (i.e. have PRNT50
titersP1:10) the primary assessment of immune responses to vac-
cination would usually be based on proportions achieving substan-
tial increases (e.g. at least a 4-fold rise) in titer after one or more
doses of JE vaccine,” [7] antibody rises were also analyzed post-
hoc as the proportion of participants with baseline titers <10
who had fold increases in neutralizing antibody between baseline
and day 28 post-vaccination of 2.00–2.99, 3.00–3.99, and P4.00.
Immunogenicity analyses were conducted on the per-protocol sub-
ject population while safety analyses included all vaccinated
subjects.
While the study was primarily descriptive, for calculation of
required sample size, we assumed the Day 28 post-
administration seroprotection would be 90% [8]. Under this
assumption, a sample size of 137 evaluable participants in each
age group (274 total) would be sufficient to demonstrate that the
observed proportion with seroprotective JE antibodies was greater
than 80% using one-sided significance levels of 0.025 and a power
of at least 90%. This total was inflated to 306 infants to allow for up
to 10% loss to follow-up in each group.
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A total of 305 children were enrolled (151 2-years-olds and 154
5-year-olds) between July and October 2007. Baseline characteris-
tics are shown in Table 1. A total of 300 subjects (98.4%) were fol-
lowed to the end of the study one year later (3 voluntarily
withdrew participation, and 2 were lost to follow-up), providing
the full 12 months of safety data post-vaccination. Of those
enrolled, 294 (96.4%) met criteria for inclusion in the per-
protocol analysis (4 were incorrectly included by age, 4 had sera
collected outside the specified time range, and 3 were missing
serologic results).
At study entry, nearly all children previously vaccinated with
IMBV had seroprotective levels of neutralizing antibodies against
JE virus (98% of 2-year-olds and 99% of 5-year-olds) (Table 2).
GMTs at baseline were high (697 among 2-year-olds and 926
among 5-year-olds). Twenty-eight days post-vaccination with
CD-JEV, all children in both age groups had seroprotective antibody
levels. Despite high baseline antibody levels, GMTs rose substan-
tially 28 days post-vaccination and persisted near these levels up
to 1 year post-vaccination; by age group, GMTs among 2-year-
olds 28 days post-vaccination were 3175 (95% CI, 2744–3672)
and among 5-year-olds were 2776 (95% CI, 2400–3210). Nearly
half of children with titers P10 pre-vaccination with CD-JEV
experienced a four-fold or greater rise in titer at 28 days post-
vaccination (Table 3). Of 144 2-year olds, 76 (52.8%) had a
four-fold or greater rise in their neutralizing antibody titer; of
146 5-year olds, 59 (40.4%) experienced such an increase. UsingTable 1
Baseline demographic characteristics of enrolled participants.
2-year-olds
(n = 151)
5-year-olds
(n = 154)
Sex, n (%) Female 79 (52.3%) 76 (49.4%)
Male 72 (47.7%) 78 (50.6%)
Ethnicity, n (%) Sinhalese 142 (94.0%) 151 (98.1%)
Sri Lankan Tamil 4 (2.6%) 0 (0.0%)
Sri Lankan Moor 5 (3.3%) 2 (1.3%)
Malay 0 (0.0%) 1 (0.6%)
Age (months), mean (SD) 24.5 (1.4) 60.4 (1.6)
Weight (kg), mean (SD) 10.9 (1.5) 16.2 (2.7)
Height (cm), mean (SD) 83.7 (4.6) 106.3 (5.5)
Table 2
Proportions seroprotecteda and geometric mean titers of JE serum neutralizing antibodies
doses (5-year-olds) of inactivated mouse-brain-derived JE vaccine.
Time post-vaccination 2-year-olds
Freq Percent (95% CI) GMT (95%
Day 0 144/147 98.0 (94.2, 99.6) 697 (551,
Day 28 147/147 100.0 (97.5, 100.0) 3175 (274
1 year 145/145 100.0 (97.5, 100.0) 3170 (267
a Seroprotection was defined as neutralizing antibody titer P1:10.
Table 3
Proportions of children with baseline neutralizing antibody titers P10 experiencing fold
vaccination with CD-JEV after previous receipt of two (2-year-olds) or three doses (5-year
Increase factor 2-year-olds (n = 144)
Freq Percent (95%
<2.00 42 29.2% (21.9, 3
2.00–2.99 12 8.3% (4.4%, 14
3.00–3.99 14 9.7% (5.4, 15.8
P4.00 76 52.8% (44.3, 6jointly WHO’s endpoint criteria for primary assessment of immune
responses as (a) the proportion of previously seronegative subjects
who reach a PRNT50 titer against Beijing-1 virus of at least 1:10
after vaccination or (b) the proportion of subjects seropositive at
baseline who achieve at least a 4-fold rise after vaccination, of
147 2-year olds, 79 [53.7% (95% CI, 45.3–62.0)] met these criteria
and of 147 5-year olds, 60 [40.8% (95% CI, 32.8–49.2)] met these
criteria.
Of the 305 children previously vaccinated with at least two
doses of IMBV and administered CD-JEV, none had immediate
reactions to the vaccine (within 30 min). Solicited local reactions
were reported almost exclusively during the first three days
post-vaccination, and all were graded as less than severe (Table 4).
Solicited systemic reactions were generally mild with anorexia,
fever, insomnia, and crying being the most commonly reported
events during the 7 days post-vaccination (Table 4). Only one sub-
ject (0.7%) in each age group had a solicited systemic reaction
graded as severe—one 2-year-old with parent-reported irritability
and one 5-year-old with parent-reported diarrhea. During the
7 days post-vaccination, parents reported unsolicited adverse reac-
tions in 15 (9.9%) 2-year-olds and 15 (9.7%) 5-year-olds (Table 4).
None were graded as severe. At the Day 28 study visit, an addi-
tional 100 unsolicited adverse events were reported among 54
(35.8%) 2-year-olds and 89 unsolicited adverse events among 54
(35.1%) 5-year-olds (Table 5). Only one of these events (<1%), diar-
rhea in a 5-year-old, was graded as severe. Twenty-six serious
adverse events were reported among 22 two-year-olds and 9 seri-
ous adverse events were reported among 8 five-year-olds up to one
year after receipt of CD-JEV. All of these were hospitalizations, and
the investigator judged that all SAEs were unrelated to receipt of
CD-JEV. There were no deaths, and all participants fully recovered.
SAEs occurring through 90 days post-vaccination with CD-JEV are
listed in Table 6.4. Discussion
Sri Lanka is similar to other countries that have used IMBVs for
the past 20–30 years to control JE but are making a transition to
the next generation of JE vaccines. Following large epidemics in
1985–1988, Sri Lanka introduced IMBV to children 1–10 years
old. Children in this study had previously received IMBV based
on the Beijing-1 JE strain. Although IMBVs require multiple doses
to maintain protective antibody titers against JE (a two-doseamong children receiving CD-JEV after previous receipt of two (2-year-olds) or three
5-year-olds
CI) Freq Percent (95% CI) GMT (95% CI)
883) 146/147 99.3 (96.3, 100.0) 926 (733, 1170)
4, 3672) 147/147 100.0 (97.5, 100.0) 2776 (2400, 3210)
4, 3758) 143/144 99.3 (96.2, 100.0) 2585 (2131, 3136)
-level increases in JE neutralizing antibodies from pre-vaccination to 28 days post-
-olds) of inactivated mouse-brain-derived JE vaccine.
5-year-olds (n = 146)
CI) Freq Percent (95% CI)
7.3) 63 43.2% (35.0, 51.6)
.1) 15 10.3% (5.9%, 16.4%)
) 9 6.2% (2.9, 11.4)
1.2) 59 40.4% (32.4, 48.8)
Table 4
Summary of solicited and unsolicited adverse reactions during the period 7 days post-vaccination.
Severity 2-year-olds (n = 151) 5-year-olds (n = 154)
na % (95% CI) na % (95% CI)
Solicited local reactions (days 0–3)
Any Any 31 20.5 (14.4; 27.9) 46 29.9 (22.8, 37.8)
Severe 0 0.0 (0.0, 2.4) 0 0.0 (0.0, 2.4)
Erythema Any 7 4.6 (1.9, 9.3) 7 4.6 (1.9; 9.1)
Severe 0 0.0 (0.0, 2.4) 0 0.0 (0.0, 2.4)
Induration Any 8 5.3 (2.3, 10.2) 9 5.8 (2.7; 10.8)
Severe 0 0.0 (0.0, 2.4) 0 0.0 (0.0, 2.4)
Pain Any 28 18.5 (12.7, 25.7) 44 28.6 (21.6; 36.4)
Severe 0 0.0 (0.0, 2.4) 0 0.0 (0.0, 2.4)
Solicited Systemic reactions (days 0–7)
Any Any 44 29.1 (22.0, 37.1) 38 24.7 (18.1, 32.3)
Severe 1 0.7 (0.0, 3.6) 1 0.7 (0.0, 3.6)
Fever Any 12 8.0 (4.2, 13.5) 16 10.4 (6.1, 16.3)
Severe 0 0.0 (0.0, 2.4) 0 0.0 (0.0, 2.4)
Anorexia Any 28 18.5 (12.7, 25.7) 16 10.4 (6.1, 16.3)
Severe 0 0.0 (0.0, 2.4) 1 0.7 (0.0, 3.6)
Crying Any 15 9.9 (5.7, 15.9) 8 5.2 (2.3, 10.0)
Severe 0 0.0 (0.0, 2.4) 0 0.0 (0.0, 2.4)
Diarrhea Any 5 3.3 (1.1, 7.6) 1 0.7 (0.0, 3.6)
Severe 0 0.0 (0.0, 2.4) 1 0.7 (0.0, 3.6)
Tiredness Any 9 6.0 (2.8, 11.0) 5 3.3 (1.1, 7.4)
Severe 0 0.0 (0.0, 2.4) 0 0.0 (0.0, 2.4)
Insomnia Any 13 8.6 (4.7, 14.3) 5 3.3 (1.1, 7.4)
Severe 0 0.0 (0.0, 2.4) 0 0.0 (0.0, 2.4)
Irritability Any 6 4.0 (1.5, 8.5) 5 3.3 (1.1, 7.4)
Severe 1 0.7 (0.0, 3.6) 0 0.0 (0.0, 2.4)
Vomiting Any 6 4.0 (1.5, 8.5) 6 3.9 (1.4, 8.3)
Severe 0 0.0 (0.0, 2.4) 0 0.0 (0.0, 2.4)
Unsolicited reactions (days 0–7)
Any Any 15 9.9 (5.7, 15.9) 15 9.7 (5.6, 15.6)
Severe 0 0.0 (0.0, 2.4) 0 0.0 (0.0, 2.4)
a Number of subjects experiencing event during specified time-period.
Table 5
Unsolicited adverse events (total and among select organ classes) among subjects Days 8–28 post-vaccination with CD-JEV.
MedDRA SYSTEM ORGAN CLASS Preferred Term 2-year-olds (n = 151) 5-year-olds (n = 154)
Subjectsa Events Subjectsa Events
n % n % n % n %
ANY NON-SERIOUS ADVERSE EVENT 54 35.8% 100 100% 54 35.1% 89 100%
EYE DISORDERS 2 1.3% 2 2.0% 1 0.6% 1 1.1%
Conjunctivitis 1 0.7% 1 1.0% 0 0.0% 0 0.0%
Eye swelling 0 0.0% 0 0.0% 1 0.6% 1 1.1%
Ocular hyperaemia 1 0.7% 1 1.0% 0 0.0% 0 0.0%
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS 16 10.6% 16 16.0% 17 11.0% 17 19.1%
Pyrexia 16 10.6% 16 16.0% 17 11.0% 17 19.1%
NERVOUS SYSTEM DISORDERS 2 1.3% 2 2.0% 0 0.0% 0 0.0%
Febrile convulsion 2 1.3% 2 2.0% 0 0.0% 0 0.0%
SKIN AND SUBCUTANEOUS TISSUE DISORDERS 4 2.6% 4 4.0% 4 2.6% 6 6.7%
Blister 1 0.7% 1 1.0% 1 0.6% 1 1.1%
Pruritus 0 0.0% 0 0.0% 1 0.6% 1 1.1%
Rash 0 0.0% 0 0.0% 1 0.6% 1 1.1%
Rash papular 0 0.0% 0 0.0% 1 0.6% 1 1.1%
Rash pruritic 1 0.7% 1 1.0% 1 0.6% 1 1.1%
Urticaria 2 1.3% 2 2.0% 1 0.6% 1 1.1%
a Each subject is counted once per ‘‘system organ class/preferred term”.
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booster doses every 4–5 years) [9], no other types of vaccines were
available internationally at that time. Although disease incidence
was dramatically reduced with introduction and wide use of IMBVover the next two decades, increases in reports of adverse events
following immunization (AEFI) negatively impacted vaccine accep-
tance by parents [10–13]. In addition, the high cost of IMBV, which
comprised nearly three quarters of the Sri Lankan vaccine budget,
Table 6
Serious adverse events among all subjects during the 90 days post-vaccination.
Subject
number
Event Onset day
post-vaccination
Severitya
2-year-olds
103–042 Lower respiratory tract infection 5 Moderate
201–062 Urticaria 19 Moderate
203–058 Viral infection 20 Moderate
103–042 Lower respiratory tract infection 24 Moderate
201–007 Febrile convulsion 27 Moderate
202–039 Lower respiratory tract infection 36 Moderate
202–039 Tonsillitis 36 Moderate
203–010 Asthma 46 Moderate
203–020 Penile swelling 47 Moderate
203–041 Viral infection 48 Mild
201–054 Viral infection 68 Moderate
201–040 Urticaria 84 Moderate
5-year-olds
202–007 Thermal burn 2 Mild
202–037 Enterobiasis 21 Moderate
203–028 Upper respiratory tract infection 81 Mild
302–039 Viral infection 89 Moderate
a Severity was graded as follows:
Mild: events require minimal or no treatment and do not interfere with the child’s
functioning.
Moderate: events result in a low level of concern with therapeutic measures.
Moderate events may cause some interference with functioning.
Severe: events interrupt the child’s functioning and may require systemic drug
therapy or other treatment. Severe events are usually incapacitating.
Life threatening: any adverse drug experience that places the child, in the view of
the investigator, at immediate risk of death from the reaction as it occurred. (The
investigator should not include a reaction that had it occurred in a more severe
form, might have caused death.)
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immunization program [10,12,14]. Moreover, inadequate supplies
of IMBV in the global market threatened the continuity of Sri Lan-
ka’s established JE vaccination programs.
IMBVs were not widely used in public health immunization
programs across JE endemic regions of Asia due to the required
multi-dose schedule, the relatively high cost, and limited duration
of protection [15,16]. In 2006 WHO recommended that IMBVs be
gradually replaced by alternative JE vaccines [16]. For Sri Lanka,
this switch was prompted when IMBV was not available in both
2007 and 2008 [14], leaving a large cohort of children unvaccinated
or partially vaccinated. The Sri Lanka Ministry of Healthcare and
Nutrition identified CD-JEV as a low-cost alternative to IMBV
[12,17]. However, before recommending its use for subsequent JE
vaccine doses in children who had previously received IMBV, the
Sri Lankan National Advisory Committee on Communicable Dis-
eases requested clinical trial data to provide evidence of vaccine
safety and immunogenicity in the Sri Lankan population.
This study answers two important questions for JE vaccination
programs considering transition from older JE vaccines to the next
generation of JE vaccines or boosting primary vaccination series
with CD-JEV. First, high titers of neutralizing antibody to JE result-
ing from vaccination with IMBV do not appear to interfere with the
boosting effect of CD-JEV. Regardless of the age of the vaccine
recipient or the number of IMBV doses previously received, the
GMT greatly increased and remained elevated one year later. Sec-
ond, although this was a small trial, the safety profile of CD-JEV
was good, with solicited or unsolicited adverse reactions and
adverse events during the first month after vaccination rarely
being graded as ‘‘severe.”
Specifying the degree of improved immune protection resulting
from the CD-JEV booster is difficult because of the high seroprotec-
tion rate noted at baseline and because specific changes in cell-
mediated immunity resulting from use of a live vaccine were not
measured in this study. In this study, the overall seroprotectionrate increased from 99% at baseline to 100% 28 days after vaccina-
tion. In a similar study in a low JE prevalence area in Korea, only
16/25 (64%) of children who previously received a two-dose pri-
mary series with IMBV had a measurable JE neutralizing antibody
titerP1:10 approximately 7 months later [18]. In this same study,
among another 16 children with history of previous receipt of
IMBV or baseline detectable JE neutralizing antibodies, 100% were
seroprotected after a single dose of CD-JEV, and among those with
documented history of previous receipt of IMBV the GMT post-
vaccination with CD-JEV was 3378. Similar results have been
reported from other countries [19,20]. The reasons for the high
seroprotection rates at baseline in our study are unknown.
In this study, there was a large increase in neutralizing antibody
GMTs following booster vaccination and, overall, about 45% of chil-
dren had at least a four-fold rise in neutralizing antibody titer. One
year later, the GMTs had not declined. Given the high seroprotec-
tion rate at baseline in our study, the increase in GMTs at 28 days
and one year after the booster dose of CD-JEV appear to be a more
meaningful measure of CD-JEV’s boosting effect. These increases
support the hypothesis that, despite the presence of preexisting
neutralizing antibodies, CD-JEV will induce a secondary immune
response after previous receipt of IMBV.
A number of clinical trials and observational studies have
shown CD-JEV to be safe and the Global Advisory Committee on
Vaccine Safety of the World Health Organization has acknowl-
edged its excellent safety profile when given in a primary series
[2,8,21–23]. Our study adds to the safety profile in children previ-
ously vaccinated with IMBV. Despite the very high baseline anti-JE
antibody titers in these children, active AEFI surveillance showed
that AEFI consistent with antibody-mediated Type I, II, or III
hypersensitivity reactions were very rare in the year following
the booster dose. No serious adverse events were attributed to
CD-JEV administration.
Our study used a ‘‘before and after design”, and as such, did not
include a control group for comparison. This design has the inher-
ent limitation of reduced internal validity and given the possibility
of potentiation of the immune response due to natural boosting by
circulating JE and dengue viruses in a study area endemic to both,
inclusion of a control group would have helped quantify changes in
immunogenicity due to CD-JEV. This was not possible, as withhold-
ing JE vaccine from a control group in a JE endemic area would be
unethical, and the unavailability of the IMBV in Sri Lanka precluded
the use of a comparator group using that vaccine. Similarly, while
we believe JE endemicity was low in our study population, we also
did not evaluate pre- or post-vaccination sera for the presence of
antibodies to other flaviviruses, such as dengue viruses. We uti-
lized the WHO-recommended PRNT50 to measure JE neutralizing
antibodies, as did the researchers in the aforementioned Korean
study, but a JE PRNT90 might have helped to differentiate baseline
JE antibodies from cross-reaction with antibodies due to exposure
to other flaviviruses such as dengue [24]. Despite these limitations,
the data from this study adds to the evidence that CD-JEV is safe
and immunogenic in children who have been primed with at least
two doses of inactivated JE vaccine. In July 2009, the Sri Lanka’s
National Advisory Committee on Communicable Diseases
approved the use of CD-JEV in children who had previously
received inactivated JE vaccine and recommended its incorporation
into the routine EPI schedule [12,25].
While several new JE vaccines are now available, CD-JEV has the
advantages of being given as a single dose, a reduced price for the
public sector, and demonstrated protection. Since 2013, Gavi, The
Vaccine Alliance has committed to provide financial support to eli-
gible countries interested in conducting JE vaccination campaigns
prior to introduction of sustainable routine infant and child JE
vaccination. Currently, nearly a dozen Asian countries, including
Sri Lanka, have national or subnational JE vaccination programs.
5928 P.R. Wijesinghe et al. / Vaccine 34 (2016) 5923–5928Five currently, Camboda, China, India, Nepal and Sri Lanka use CD-
JEV vaccine [2]. With Gavi support now available and the safety,
effectiveness, and feasibility of CD-JEV now established, other
countries in Asia and the Western Pacific have the opportunity to
introduce CD-JEV to combat this disease of public health
importance.
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